Abstract
The clinical benefit of a new genomic instrument, the 70-gene signature
for breast cancer patients, is being evaluated in a randomised clinical
trial. The early, controlled implementation process is supported by a
Constructive Technology Assessment to help decision-making in an
uncertain time of development
| Original language | English |
|---|---|
| Pages (from-to) | 52-54 |
| Number of pages | 3 |
| Journal | EJHP practice |
| Volume | 14 |
| Issue number | 6 |
| Publication status | Published - 2008 |
